The pharmacokinetic considerations and adverse effects of DDP-4 inhibitors
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The pharmacokinetic considerations and adverse effects of DDP-4 inhibitors
Authors
Keywords
-
Journal
Expert Opinion on Drug Metabolism & Toxicology
Volume 10, Issue 6, Pages 787-812
Publisher
Informa Healthcare
Online
2014-04-19
DOI
10.1517/17425255.2014.907274
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice
- (2013) Kathryn Aston-Mourney et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Renal Impairment Has No Clinically Relevant Effect on the Long-Term Exposure of Linagliptin in Patients With Type 2 Diabetes
- (2013) Christian Friedrich et al. AMERICAN JOURNAL OF THERAPEUTICS
- Differences in metabolic parameters and cardiovascular risk between American Diabetes Association and World Health Organization definition of impaired fasting glucose in European Caucasian subjects: a cross-sectional study
- (2013) Theodosios D. Filippatos et al. Archives of Medical Science
- Gemigliptin, a novel dipeptidyl peptidase 4 inhibitor: first new anti-diabetic drug in the history of Korean pharmaceutical industry
- (2013) Sung-Ho Kim et al. ARCHIVES OF PHARMACAL RESEARCH
- A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site
- (2013) Mika Nabeno et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetics of Empagliflozin and Linagliptin After Coadministration in Healthy Male Volunteers
- (2013) Christian Friedrich et al. CLINICAL THERAPEUTICS
- The Place of GLP-1–Based Therapy in Diabetes Management: Differences Between DPP-4 Inhibitors and GLP-1 Receptor Agonists
- (2013) Dara L. Eckerle Mize et al. Current Diabetes Reports
- Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors
- (2013) A. E. Butler et al. DIABETES
- Probable linagliptin-induced liver toxicity: A case report
- (2013) E. Kutoh DIABETES & METABOLISM
- A Critical Analysis of the Clinical Use of Incretin-Based Therapies: The benefits by far outweigh the potential risks
- (2013) M. A. Nauck DIABETES CARE
- A Critical Analysis of the Clinical Use of Incretin-Based Therapies: Are the GLP-1 therapies safe?
- (2013) P. C. Butler et al. DIABETES CARE
- Standards of Medical Care in Diabetes--2014
- (2013) DIABETES CARE
- Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus
- (2013) T. Kadowaki et al. DIABETES OBESITY & METABOLISM
- Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials
- (2013) M. Monami et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone
- (2013) E. J. Rhee et al. DIABETES OBESITY & METABOLISM
- The effect of dipeptidyl peptidase-IV inhibition on bone in a mouse model of type 2 diabetes
- (2013) Emily Jane Gallagher et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Dipeptidyl peptidase-4 inhibitors and angioedema: a class effect?
- (2013) Y. Saisho et al. DIABETIC MEDICINE
- Effect of ABCB1 polymorphisms and atorvastatin on sitagliptin pharmacokinetics in healthy volunteers
- (2013) Christina L. Aquilante et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis
- (2013) Andre Scheen Expert Opinion On Drug Safety
- The development of angioedema in a patient with type 2 diabetes due to a novel dipeptidyl peptidase-IV inhibitor, anagliptin
- (2013) Hidetaka Hamasaki et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Pharmacokinetics of vildagliptin in patients with varying degrees of renal impairment
- (2013) Yan-Ling He et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with Type 2 diabetes
- (2013) Masayuki Yamaguchi et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Clinically relevant reductions in HbA1cwithout hypoglycaemia: results across four studies of saxagliptin
- (2013) C. S. Karyekar et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- The DPP-4 Inhibitor Linagliptin Restores β-Cell Function and Survival in Human Isolated Islets Through GLP-1 Stabilization
- (2013) Payal Shah et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial
- (2013) Anthony H Barnett et al. LANCET
- Small High-Density Lipoprotein (HDL) Subclasses are Increased with Decreased Activity of HDL-Associated Phospholipase A2 in Subjects with Prediabetes
- (2013) Theodosios D. Filippatos et al. LIPIDS
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
- (2013) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans
- (2013) Yoshinobu Nakamaru et al. XENOBIOTICA
- Has pancreatic damage from glucagon suppressing diabetes drugs been underplayed?
- (2013) D. Cohen BMJ-British Medical Journal
- Dipeptidyl Peptidase‐4 Inhibitors Attenuate Endothelial Function as Evaluated by Flow‐Mediated Vasodilatation in Type 2 Diabetic Patients
- (2013) Makoto Ayaori et al. Journal of the American Heart Association
- A Case Report of Bullous Pemphigoid Induced by Dipeptidyl Peptidase-4 Inhibitors
- (2013) Iman Aouidad et al. JAMA Dermatology
- Glucagonlike Peptide 1–Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus
- (2013) Sonal Singh et al. JAMA Internal Medicine
- Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes
- (2013) Miyako Kishimoto Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Pharmacokinetics of Empagliflozin, a Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitor, Coadministered with Sitagliptin in Healthy Volunteers
- (2012) Tobias Brand et al. ADVANCES IN THERAPY
- Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): A highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
- (2012) Tomohiro Yoshida et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Pharmacokinetics of linagliptin in subjects with hepatic impairment
- (2012) Ulrike Graefe-Mody et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- A Review of Time Courses and Predictors of Lipid Changes with Fenofibric Acid-Statin Combination
- (2012) Theodosios D. Filippatos CARDIOVASCULAR DRUGS AND THERAPY
- Pharmacokinetic Study of Saxagliptin in Healthy Chinese Subjects
- (2012) Haiyan Li et al. CLINICAL DRUG INVESTIGATION
- Clinical Pharmacokinetics and Pharmacodynamics of Vildagliptin
- (2012) Yan-Ling He CLINICAL PHARMACOKINETICS
- Clinical Pharmacokinetics and Pharmacodynamics of Linagliptin
- (2012) Ulrike Graefe-Mody et al. CLINICAL PHARMACOKINETICS
- Effects of Ketoconazole and Rifampicin on the Pharmacokinetics of Gemigliptin, a Dipeptidyl Peptidase-IV Inhibitor: A Crossover Drug–Drug Interaction Study in Healthy Male Korean Volunteers
- (2012) Yook-Hwan Noh et al. CLINICAL THERAPEUTICS
- Recent Advances in Non-Peptidomimetic Dipeptidyl Peptidase 4 Inhibitors: Medicinal Chemistry and Preclinical Aspects
- (2012) Y. Liu et al. CURRENT MEDICINAL CHEMISTRY
- Chronic GLP-1 Receptor Activation by Exendin-4 Induces Expansion of Pancreatic Duct Glands in Rats and Accelerates Formation of Dysplastic Lesions and Chronic Pancreatitis in the KrasG12DMouse Model
- (2012) Belinda Gier et al. DIABETES
- Cardiovascular effects of the DPP-4 inhibitors
- (2012) Tessey Jose et al. Diabetes & Vascular Disease Research
- Sitagliptin-Associated Angioedema
- (2012) A. R. Gosmanov et al. DIABETES CARE
- No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects
- (2012) R. A. Smulders et al. DIABETES OBESITY & METABOLISM
- Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus
- (2012) G. Schernthaner et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study
- (2012) Y. Seino et al. DIABETES OBESITY & METABOLISM
- A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes
- (2012) S. J. Yang et al. DIABETES OBESITY & METABOLISM
- Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis
- (2012) M. Pendergrass et al. DIABETES OBESITY & METABOLISM
- Linagliptin
- (2012) Emma D. Deeks DRUGS
- Suicide attempt by an overdose of sitagliptin, an oral hypoglycemic agent: A case report and a review of the literature
- (2012) Shinya Furukawa et al. ENDOCRINE JOURNAL
- Elevated Amylase and Lipase Levels in Patients Using Glucagonlike Peptide-1 Receptor Agonists or Dipeptidyl-Peptidase-4 Inhibitors in the Outpatient Setting
- (2012) Howard Lando et al. Endocrine Practice
- A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations
- (2012) Sayaka Fukuda-Tsuru et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes
- (2012) André J Scheen Expert Opinion on Drug Metabolism & Toxicology
- Pancreatitis with Pancreatic Tail Swelling Associated with Incretin-based Therapies Detected Radiologically in Two Cases of Diabetic Patients with End-Stage Renal Disease
- (2012) Hirosuke Nakata et al. INTERNAL MEDICINE
- Efficacy and Tolerability of the DPP-4 Inhibitor Alogliptin Combined with Pioglitazone, in Metformin-Treated Patients with Type 2 Diabetes
- (2012) R. A. DeFronzo et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Dipeptidyl Peptidase IV Inhibition Does Not Adversely Affect Immune or Virological Status in HIV Infected Men And Women: A Pilot Safety Study
- (2012) Scott R. Goodwin et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes
- (2012) Vivian Fonseca et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice
- (2012) Hannelouise Kissow et al. REGULATORY PEPTIDES
- Pharmacokinetics and metabolism of [14C]anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in humans
- (2012) Shinji Furuta et al. XENOBIOTICA
- Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor
- (2012) Aiying Wang et al. BMC Pharmacology & Toxicology
- Psoriasiform eruption triggered by a dipeptidyl peptidase IV inhibitor
- (2011) Albert Mas-Vidal et al. AUSTRALASIAN JOURNAL OF DERMATOLOGY
- Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor
- (2011) Noriyasu Kato et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects
- (2011) Vijay V. Upreti et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Effect of Multiple Oral Doses of Linagliptin on the Steady-State Pharmacokinetics of a Combination Oral Contraceptive in Healthy Female Adults
- (2011) Christian Friedrich et al. CLINICAL DRUG INVESTIGATION
- Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Saxagliptin
- (2011) David W. Boulton et al. CLINICAL PHARMACOKINETICS
- Saxagliptin: A Clinical Review in the Treatment of Type 2 Diabetes Mellitus
- (2011) Deanna S. Kania et al. CLINICAL THERAPEUTICS
- Pharmacokinetic, Pharmacodynamic, and Tolerability Profiles of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin: A 4-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIa Study in Japanese Type 2 Diabetes Patients
- (2011) Yoshiharu Horie et al. CLINICAL THERAPEUTICS
- Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials
- (2011) Matteo Monami et al. CURRENT MEDICAL RESEARCH AND OPINION
- Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus
- (2011) Priscilla L Hollander et al. Diabetes & Vascular Disease Research
- DPP-4 Inhibitors: Impact on glycemic control and cardiovascular risk factors
- (2011) D. Dicker DIABETES CARE
- The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide
- (2011) A. H. Barnett DIABETES OBESITY & METABOLISM
- Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects
- (2011) C. G. Patel et al. DIABETES OBESITY & METABOLISM
- Do antidiabetic medications play a specific role in differentiated thyroid cancer compared to other cancer types?
- (2011) E. Fröhlich et al. DIABETES OBESITY & METABOLISM
- Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin*
- (2011) U. Graefe-Mody et al. DIABETES OBESITY & METABOLISM
- DPP-IV inhibitor may affect spermatogenesis
- (2011) Hatsuki Hibi et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Efficacy and safety of saxagliptin in drug-naïve Asian patients with type 2 diabetes mellitus: a randomized controlled trial
- (2011) Chang Yu Pan et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Rhabdomyolysis precipitated by a sitagliptin-atorvastatin drug interaction
- (2011) R. Bhome et al. DIABETIC MEDICINE
- Reduction of both beta cell death and alpha cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice
- (2011) Y. Takeda et al. DIABETOLOGIA
- Pharmacokinetic drug interaction between gemfibrozil and sitagliptin in healthy Indian male volunteers
- (2011) Arun K. P. et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Evaluation of the pharmacokinetic interaction after multiple oral doses of linagliptin and digoxin in healthy volunteers
- (2011) C. Friedrich et al. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
- Excretion of the dipeptidyl peptidase-4 inhibitor linagliptin in rats is primarily by biliary excretion and P-gp-mediated efflux
- (2011) Holger Fuchs et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia
- (2011) Aris P Agouridis et al. EXPERT OPINION ON PHARMACOTHERAPY
- Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia
- (2011) Theodosios D Filippatos et al. EXPERT OPINION ON PHARMACOTHERAPY
- Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes
- (2011) Thomas Forst et al. EXPERT OPINION ON PHARMACOTHERAPY
- Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies
- (2011) Michael Elashoff et al. GASTROENTEROLOGY
- A Case of Drug-induced Hepatic Injury Associated with Sitagliptin
- (2011) Megumi Toyoda-Akui et al. INTERNAL MEDICINE
- Incretin-based therapies - review of the physiology, pharmacology and emerging clinical experience
- (2011) J. H. Martin et al. INTERNAL MEDICINE JOURNAL
- Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes
- (2011) D. Serra et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Effect of linagliptin (BI 1356) on the steady-state pharmacokinetics of simvastatin
- (2011) U. Graefe-Mody et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase-4 inhibitor linagliptin and pioglitazone in healthy volunteers
- (2011) E.U. Graefe-Mody et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects
- (2011) A. Karim et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Effect of linagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers
- (2011) E.U. Graefe-Mody et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase IV inhibitor LC15-0444 and pioglitazone in healthy volunteers
- (2011) Sung Eun Kim et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Does Not Affect the Pharmacokinetics of Ethinyl Estradiol or Norethindrone in Healthy Female Subjects
- (2011) Elizabeth Migoya et al. JOURNAL OF CLINICAL PHARMACOLOGY
- The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials
- (2011) L. Cai et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Drug eruption caused by sitagliptin, a dipeptidyl peptidase-IV inhibitor
- (2011) Keiko TANAKA et al. JOURNAL OF DERMATOLOGY
- Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin
- (2011) K. Skandalis et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Elevated Hepatic Enzymes Potentially Associated with Sitagliptin
- (2010) Benjamin N Gross et al. ANNALS OF PHARMACOTHERAPY
- Sitagliptin-Associated Drug Allergy: Review of Spontaneous Adverse Event Reports
- (2010) Shrey Desai ARCHIVES OF INTERNAL MEDICINE
- Dipeptidylpeptitase-4 Inhibitors (Gliptins)
- (2010) André J. Scheen CLINICAL PHARMACOKINETICS
- Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: A phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male japanese subjects
- (2010) Akiko Sarashina et al. CLINICAL THERAPEUTICS
- Combination of Fenofibrate with Non-Statin Drug Regimens
- (2010) A. P. Agouridis et al. CURRENT PHARMACEUTICAL DESIGN
- Obesity and Arterial Compliance Alterations
- (2010) Alexander Seifalian et al. Current Vascular Pharmacology
- Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin: A retrospective observational pharmacy claims analysis
- (2010) R. Garg et al. DIABETES CARE
- An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials
- (2010) M. Ligueros-Saylan et al. DIABETES OBESITY & METABOLISM
- Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects
- (2010) S. Kasichayanula et al. DIABETES OBESITY & METABOLISM
- Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review
- (2010) C. F. Deacon DIABETES OBESITY & METABOLISM
- Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus
- (2010) Masatoshi Kikuchi et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Severe leucopenia associated with Sitagliptin use
- (2010) Dario Pitocco et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus
- (2010) André J. Scheen et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Angio-oedema induced by dual dipeptidyl peptidase inhibitor and angiotensin II receptor blocker: a first case report
- (2010) S. Skalli et al. DIABETIC MEDICINE
- The Metabolism and Disposition of the Oral Dipeptidyl Peptidase-4 Inhibitor, Linagliptin, in Humans
- (2010) S. Blech et al. DRUG METABOLISM AND DISPOSITION
- Assessment of the Pharmacokinetic Interaction between the Novel DPP-4 Inhibitor Linagliptin and a Sulfonylurea, Glyburide, in Healthy Subjects
- (2010) Ulrike Graefe-Mody et al. Drug Metabolism and Pharmacokinetics
- The dipeptidyl peptidase IV family in cancer and cell biology
- (2010) Denise M. T. Yu et al. FEBS Journal
- Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes
- (2010) Debora Williams-Herman et al. BMC Endocrine Disorders
- Biochemistry, pharmacokinetics, and toxicology of a potent and selective DPP8/9 inhibitor
- (2009) Jia-Jing Wu et al. BIOCHEMICAL PHARMACOLOGY
- Genetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T cell-dependent immune responses
- (2009) Kalpit A Vora et al. BMC IMMUNOLOGY
- Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers
- (2009) Kyoung Soo Lim et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition
- (2009) Mark Kirby et al. CLINICAL SCIENCE
- Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes
- (2009) Yan-Ling He et al. CURRENT MEDICAL RESEARCH AND OPINION
- Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study
- (2009) Debora Williams-Herman et al. CURRENT MEDICAL RESEARCH AND OPINION
- Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects
- (2009) E. U. Graefe-Mody et al. CURRENT MEDICAL RESEARCH AND OPINION
- Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide
- (2009) David D. Dore et al. CURRENT MEDICAL RESEARCH AND OPINION
- Beneficial Endocrine but Adverse Exocrine Effects of Sitagliptin in the Human Islet Amyloid Polypeptide Transgenic Rat Model of Type 2 Diabetes: Interactions With Metformin
- (2009) A. V. Matveyenko et al. DIABETES
- The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone
- (2009) R. A. DeFronzo et al. DIABETES CARE
- Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1cwithout causing weight gain or increased hypoglycaemia
- (2009) J. Rosenstock et al. DIABETES OBESITY & METABOLISM
- Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients
- (2009) T. Heise et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy
- (2009) R. E. Pratley et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes
- (2009) T. Vilsbøll et al. DIABETES OBESITY & METABOLISM
- Pharmacokinetics of the Dipeptidyl Peptidase 4 Inhibitor Saxagliptin in Rats, Dogs, and Monkeys and Clinical Projections
- (2009) A. Fura et al. DRUG METABOLISM AND DISPOSITION
- Dipeptidyl Peptidase-IV Inhibitor Use Associated With Increased Risk of ACE Inhibitor-Associated Angioedema
- (2009) Nancy J. Brown et al. HYPERTENSION
- Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial
- (2009) A. R. Chacra et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Saxagliptin Added to a Thiazolidinedione Improves Glycemic Control in Patients with Type 2 Diabetes and Inadequate Control on Thiazolidinedione Alone
- (2009) Priscilla Hollander et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Multiple Doses of Sitagliptin, a Selective DPP-4 Inhibitor, Do Not Meaningfully Alter Pharmacokinetics and Pharmacodynamics of Warfarin
- (2009) D. Hamish Wright et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Effect of Sitagliptin on the Pharmacokinetics of Simvastatin
- (2009) Arthur J. Bergman et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Coadministration of Pioglitazone or Glyburide and Alogliptin: Pharmacokinetic Drug Interaction Assessment in Healthy Participants
- (2009) Aziz Karim et al. JOURNAL OF CLINICAL PHARMACOLOGY
- A Thorough QTc Study to Assess the Effect of Sitagliptin, a DPP4 Inhibitor, on Ventricular Repolarization in Healthy Subjects
- (2009) Daniel M. Bloomfield et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans
- (2009) Holger Fuchs et al. JOURNAL OF PHARMACY AND PHARMACOLOGY
- Rhabdomyolysis Caused by a Potential Sitagliptin-Lovastatin Interaction
- (2009) Robert V DiGregorio et al. PHARMACOTHERAPY
- Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?
- (2009) Roger Yazbeck et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects
- (2008) Goutam C. Mistry et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects
- (2008) R CHRISTOPHER et al. CLINICAL THERAPEUTICS
- Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: A randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes
- (2008) P COVINGTON et al. CLINICAL THERAPEUTICS
- Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: A dose—block-randomized, double-blind, placebo-controlled, ascending single-dose, phase I study
- (2008) Kyoung Soo Lim et al. CLINICAL THERAPEUTICS
- Dipeptidyl Peptidase IV Inhibition With MK0431 Improves Islet Graft Survival in Diabetic NOD Mice Partially via T-Cell Modulation
- (2008) S.-J. Kim et al. DIABETES
- Efficacy and tolerability of vildagliptin in drug-nave patients with type 2 diabetes and mild hyperglycaemia
- (2008) W. A. Scherbaum et al. DIABETES OBESITY & METABOLISM
- Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited
- (2008) B. F. Burkey et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes*
- (2008) R. Scott et al. DIABETES OBESITY & METABOLISM
- Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes
- (2008) J. Rosenstock et al. DIABETES OBESITY & METABOLISM
- Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea*
- (2008) A. J. Garber et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes
- (2008) Kenji Nonaka et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use
- (2008) D. P. Kao et al. DIABETIC MEDICINE
- Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use. But what about the amiodarone?
- (2008) B. J. Boucher DIABETIC MEDICINE
- Absorption, Metabolism, and Excretion of [14C]Vildagliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, in Humans
- (2008) H. He et al. DRUG METABOLISM AND DISPOSITION
- Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys
- (2008) Bumsup Lee et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Treatment of hyperlipidaemia with fenofibrate and related fibrates
- (2008) Theodosios Filippatos et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study
- (2008) M. A. Nauck et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of BI 1356, an Inhibitor of Dipeptidyl Peptidase 4, in Healthy Male Volunteers
- (2008) S. Hüttner et al. JOURNAL OF CLINICAL PHARMACOLOGY
- (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a Novel Xanthine-Based Dipeptidyl Peptidase 4 Inhibitor, Has a Superior Potency and Longer Duration of Action Compared with Other Dipeptidyl Peptidase-4 Inhibitors
- (2008) L. Thomas et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- AMH (Australian Medicines Handbook, 2007 Edition)
- (2007) S E Tett CLINICAL PHARMACOLOGY & THERAPEUTICS
- Postmenopausal Hormone Therapy for Disease Prevention: Have We Learned Any Lessons from the Past?
- (2007) J E Rossouw CLINICAL PHARMACOLOGY & THERAPEUTICS
- The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome
- (2007) T. D. Filippatos et al. DIABETES OBESITY & METABOLISM
- Dipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor–Associated Angioedema
- (2007) James Brian Byrd et al. HYPERTENSION
- Vildagliptin, a Novel Dipeptidyl Peptidase IV Inhibitor, Has No Pharmacokinetic Interactions With the Antihypertensive Agents Amlodipine, Valsartan, and Ramipril in Healthy Subjects
- (2007) Yan-Ling He et al. JOURNAL OF CLINICAL PHARMACOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now